BRPI0922774B8 - composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos. - Google Patents

composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.

Info

Publication number
BRPI0922774B8
BRPI0922774B8 BRPI0922774A BRPI0922774A BRPI0922774B8 BR PI0922774 B8 BRPI0922774 B8 BR PI0922774B8 BR PI0922774 A BRPI0922774 A BR PI0922774A BR PI0922774 A BRPI0922774 A BR PI0922774A BR PI0922774 B8 BRPI0922774 B8 BR PI0922774B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compound
hydrochloride dihydrate
obtaining
producing
Prior art date
Application number
BRPI0922774A
Other languages
English (en)
Inventor
De Faveri Carla
Anton Martin Huber Florian
Lopes de Diego Heidi
Original Assignee
Biotie Therapies Corp
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922774(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp, H Lundbeck As filed Critical Biotie Therapies Corp
Publication of BRPI0922774A2 publication Critical patent/BRPI0922774A2/pt
Publication of BRPI0922774B1 publication Critical patent/BRPI0922774B1/pt
Publication of BRPI0922774B8 publication Critical patent/BRPI0922774B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Abstract

composto, processo para obtenção de um composto, composição farmacêutica, e, processo para produzir uma composição farmacêutica a presente invenção se refere ao cloridrato de nalmefeno di-hidratado, aos processos de manufatura de cloridrato de nalmefeno di-hidratado, a uma composição farmacêutica compreendendo cloridratro de nalmefeno di-hidratado e a um método de tratamento compreendendo administrar cloridrato de nalmefeno di-hidratado.
BRPI0922774A 2008-12-05 2009-12-04 composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos. BRPI0922774B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801729 2008-12-05
DKPA200801729 2008-12-05
PCT/DK2009/050320 WO2010063292A1 (en) 2008-12-05 2009-12-04 Nalmefene hydrochloride dihydrate

Publications (3)

Publication Number Publication Date
BRPI0922774A2 BRPI0922774A2 (pt) 2017-07-11
BRPI0922774B1 BRPI0922774B1 (pt) 2020-10-13
BRPI0922774B8 true BRPI0922774B8 (pt) 2021-05-25

Family

ID=41571731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922774A BRPI0922774B8 (pt) 2008-12-05 2009-12-04 composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.

Country Status (31)

Country Link
US (2) US8530495B2 (pt)
EP (2) EP2300479B1 (pt)
JP (3) JP6055183B2 (pt)
KR (2) KR20110089333A (pt)
CN (2) CN104211707B (pt)
AR (1) AR074507A1 (pt)
AT (1) ATE546453T1 (pt)
AU (1) AU2009321898B2 (pt)
BR (1) BRPI0922774B8 (pt)
CA (1) CA2744932C (pt)
CL (1) CL2011001331A1 (pt)
CO (1) CO6362012A2 (pt)
CY (2) CY1112643T1 (pt)
DK (2) DK2300479T3 (pt)
EA (1) EA018948B1 (pt)
ES (2) ES2380297T3 (pt)
HK (1) HK1205108A1 (pt)
HR (2) HRP20120247T1 (pt)
IL (1) IL213112A (pt)
MX (1) MX2011005865A (pt)
MY (1) MY149028A (pt)
NZ (1) NZ593874A (pt)
PL (2) PL2300479T3 (pt)
PT (2) PT2441766E (pt)
RS (2) RS53415B (pt)
SG (1) SG171910A1 (pt)
SI (2) SI2441766T1 (pt)
SM (2) SMT201200014B (pt)
TW (1) TWI465450B (pt)
UA (1) UA102128C2 (pt)
WO (1) WO2010063292A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
US20140155608A1 (en) 2012-05-03 2014-06-05 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
US20160058754A1 (en) * 2013-04-17 2016-03-03 H. Lundbeck A/S Nalmefene for Treatment of Patients with Anxiety Disorder
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
US20170042887A1 (en) 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
TWI681954B (zh) * 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
US20240109907A1 (en) 2021-01-28 2024-04-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
EP1708690B1 (en) * 2003-11-17 2016-07-20 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
PL2137189T3 (pl) 2007-03-06 2015-12-31 SpecGx LLC Sposób wytwarzania czwartorzędowych N-alkilowych soli alkaloidu morfinanowego
US8399475B2 (en) * 2007-04-12 2013-03-19 Mallinckrodt Llc Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
JP6591759B2 (ja) 2019-10-16
RS52255B (en) 2012-10-31
MY149028A (en) 2013-06-28
EP2441766B1 (en) 2014-06-25
ATE546453T1 (de) 2012-03-15
CN104211707B (zh) 2017-04-12
HK1205108A1 (en) 2015-12-11
DK2441766T3 (da) 2014-07-21
CY1112643T1 (el) 2016-02-10
JP6591944B2 (ja) 2019-10-16
WO2010063292A1 (en) 2010-06-10
SG171910A1 (en) 2011-07-28
TW201022273A (en) 2010-06-16
US8530495B2 (en) 2013-09-10
ES2380297T3 (es) 2012-05-10
CN102325778B (zh) 2014-08-13
US8754217B2 (en) 2014-06-17
AU2009321898B2 (en) 2014-10-02
EP2300479B1 (en) 2012-02-22
CA2744932A1 (en) 2010-06-10
SMT201400113B (it) 2014-11-10
CO6362012A2 (es) 2012-01-20
IL213112A (en) 2013-06-27
KR20110089333A (ko) 2011-08-05
NZ593874A (en) 2013-02-22
KR20170008893A (ko) 2017-01-24
SI2441766T1 (sl) 2014-12-31
CL2011001331A1 (es) 2011-08-26
EP2441766A1 (en) 2012-04-18
JP6055183B2 (ja) 2016-12-27
RS53415B (en) 2014-12-31
TWI465450B (zh) 2014-12-21
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
AR074507A1 (es) 2011-01-19
JP2017025079A (ja) 2017-02-02
US20110251228A1 (en) 2011-10-13
PT2441766E (pt) 2014-08-05
HRP20120247T1 (hr) 2012-05-31
CN102325778A (zh) 2012-01-18
EA201170753A1 (ru) 2011-12-30
MX2011005865A (es) 2011-09-06
IL213112A0 (en) 2011-07-31
PL2441766T3 (pl) 2014-09-30
PL2300479T3 (pl) 2012-06-29
ES2488165T3 (es) 2014-08-26
DK2300479T3 (da) 2012-03-26
SMT201200014B (it) 2012-07-10
EP2300479A1 (en) 2011-03-30
US20130338365A1 (en) 2013-12-19
HRP20140648T1 (hr) 2014-09-26
AU2009321898A1 (en) 2011-07-14
BRPI0922774B1 (pt) 2020-10-13
EA018948B1 (ru) 2013-11-29
BRPI0922774A2 (pt) 2017-07-11
JP2015134785A (ja) 2015-07-27
CY1115381T1 (el) 2017-01-04
UA102128C2 (en) 2013-06-10
PT2300479E (pt) 2012-04-10
JP2012510954A (ja) 2012-05-17
SI2300479T1 (sl) 2012-07-31

Similar Documents

Publication Publication Date Title
BRPI0922774B8 (pt) composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BR112012027509A2 (pt) composto, processo para a preparação de composto, composição farmacêutica, uso de composto, e, método
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
BRPI0906786A2 (pt) Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BR112014010391A2 (pt) composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BRPI0714539B8 (pt) processo para obtenção de forma de dosagem farmaceutica de liberação prolongada de opioides
BRPI0720070A2 (pt) Processo para produção de produtos de tecido
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
BRPI0702295A (pt) produto de adição de açúcar flavonóide, composição, uso de um produto de adição de açúcar flavonóide, e, processo para a fabricação de produto de adição
EA201290416A1 (ru) Новые спиропиперидиновые соединения
BRPI1010970A2 (pt) solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento
WO2009023434A3 (en) Method for stabilizing phenylephrine
BRPI0817721A2 (pt) Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
BRPI1007654A2 (pt) composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica
BRPI0911709A2 (pt) composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
BRPI0817445A2 (pt) composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto
EP2280052A4 (en) FLUORESCENT COMPOUNDS FOR THE DIAGNOSIS OF INFECTIONS, THEIR PREPARATION AND USES
BRPI1015559A2 (pt) forma hemi-hidratada, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento de um distúrbio inflamatório, e, produto de combinação.
BR112022000684A2 (pt) Monotosilato de umbralisibe, processo para preparar uma forma amorfa, forma amorfa de monotosilato de umbralisibe, composição farmacêutica, e, método de tratamento de doença
BRPI0923296A2 (pt) Diguanilato ciclase mutante, método para a fabricação de diguanilato ciclase mutante, processo para a produção de monofosfato de diguanosina cíclico, e, lote
BRPI0907097A2 (pt) Éster derivado de 2-amino-2-fenil-alcanol, processo de preparação de um derivado e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF